Brian Park, PharmD

Drug Information Specialist https://www.clinicalpainadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Pain

FDA Requires Boxed Warning Update for Benzodiazepines

Brian Park, PharmD

September 25, 2020

Benzodiazepines are widely used to treat a variety of conditions including anxiety disorders, insomnia and seizures.

Chronic Pain

Bafiertam Now Available for Relapsing Forms of Multiple Sclerosis

Brian Park, PharmD

September 11, 2020

Bafiertam, a novel fumarate bioequivalent alternative to its prodrug dimethyl fumarate, is now available for multiple sclerosis.

Post-Surgical Pain

XaraColl Implant Approved for Postop Pain Following Hernia Repair

Brian Park, PharmD

September 3, 2020

The FDA has approved XaraColl® implant for acute postsurgical pain relief for up to 24 hours in adults following open inguinal hernia repair.

General Pain

Amisulpride Postoperative Nausea, Vomiting Drug Launched

Brian Park, PharmD

August 28, 2020

Barhemsys, a selective dopamine-2 and dopamine-3 receptor antagonist, is indicated for the prevention of postoperative nausea and vomiting.

Musculoskeletal Pain

Orphengesic Forte Now Available for Acute Musculoskeletal Pain

Brian Park, PharmD

August 27, 2020

Orphengesic Forte for the symptomatic relief of mild to moderate pain of acute musculoskeletal disorders now available.

Opioid Addiction

Extended Shelf Life Approved for Naloxone Nasal Spray

Brian Park, PharmD

August 20, 2020

Naloxone is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose.

Acute Pain

New IV Opioid Analgesic Approved for Acute Pain

Brian Park, PharmD

August 11, 2020

Olinvyk is indicated for short-term intravenous use in hospitals or other controlled clinical settings.

Migraine & Headache

Atogepant Reduces Monthly Migraine Days in Phase 3 Prevention Trial

Brian Park, PharmD

July 31, 2020

The ADVANCE study included 910 adults who experienced 4 to 14 migraines per month.

Opioid Addiction

FDA Requires Labeling Changes for Opioids to Include Information About Naloxone

Brian Park, PharmD

July 28, 2020

The FDA has announced that it is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder to include new recommendations about naloxone to the prescribing information.